241 related articles for article (PubMed ID: 20577993)
1. Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies.
Valdez BC; Andersson BS
Environ Mol Mutagen; 2010 Jul; 51(6):659-68. PubMed ID: 20577993
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Alatrash G; Thall PF; Valdez BC; Fox PS; Ning J; Garber HR; Janbey S; Worth LL; Popat U; Hosing C; Alousi AM; Kebriaei P; Shpall EJ; Jones RB; de Lima M; Rondon G; Chen J; Champlin RE; Andersson BS
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1792-1800. PubMed ID: 27377901
[TBL] [Abstract][Full Text] [Related]
3. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Lech-Maranda E; Korycka A; Robak T
Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
[TBL] [Abstract][Full Text] [Related]
4. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
6. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog.
Faderl S; Gandhi V; Keating MJ; Jeha S; Plunkett W; Kantarjian HM
Cancer; 2005 May; 103(10):1985-95. PubMed ID: 15803490
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in Pediatric Patients with Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia Consortium Study.
Soni S; Abdel-Azim H; McManus M; Nemecek E; Sposto R; Woolfrey A; Frangoul H
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1134-1141. PubMed ID: 28396162
[TBL] [Abstract][Full Text] [Related]
8. Clofarabine: a new treatment option for patients with acute myeloid leukemia.
Larson ML; Venugopal P
Expert Opin Pharmacother; 2009 Jun; 10(8):1353-7. PubMed ID: 19463072
[TBL] [Abstract][Full Text] [Related]
9. Clofarabine in leukemia.
Ghanem H; Jabbour E; Faderl S; Ghandhi V; Plunkett W; Kantarjian H
Expert Rev Hematol; 2010 Feb; 3(1):15-22. PubMed ID: 21082931
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of anti-cancer action and pharmacology of clofarabine.
Zhenchuk A; Lotfi K; Juliusson G; Albertioni F
Biochem Pharmacol; 2009 Dec; 78(11):1351-9. PubMed ID: 19576186
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow CFU-GM and human tumor xenograft efficacy of three antitumor nucleoside analogs.
Bagley RG; Roth S; Kurtzberg LS; Rouleau C; Yao M; Crawford J; Krumbholz R; Lovett D; Schmid S; Teicher BA
Int J Oncol; 2009 May; 34(5):1329-40. PubMed ID: 19360345
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
13. Novel purine nucleoside analogues for hematological malignancies.
Korycka A; Lech-Marańda E; Robak T
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):123-36. PubMed ID: 18537755
[TBL] [Abstract][Full Text] [Related]
14. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
[TBL] [Abstract][Full Text] [Related]
15. Haploidentical Bone Marrow Transplantation With Clofarabine and Busulfan Conditioning for a Child With Multiple Recurrent Acute Lymphoblastic Leukemia.
Aoki Y; Miyawaki R; Imai K; Takagi M; Kajiwara M; Ishiwata Y; Yasuhara M; Morio T; Mizutani S; Tomizawa D
J Pediatr Hematol Oncol; 2016 Jan; 38(1):e39-41. PubMed ID: 26523380
[TBL] [Abstract][Full Text] [Related]
16. Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies.
Magenau J; Tobai H; Pawarode A; Braun T; Peres E; Reddy P; Kitko C; Choi S; Yanik G; Frame D; Harris A; Erba H; Kujawski L; Elenitoba-Johnson K; Sanks J; Jones D; Paczesny S; Ferrara J; Levine J; Mineishi S
Blood; 2011 Oct; 118(15):4258-64. PubMed ID: 21841163
[TBL] [Abstract][Full Text] [Related]
17. Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup.
Huguet F; Leguay T; Raffoux E; Rousselot P; Vey N; Pigneux A; Ifrah N; Dombret H
Leuk Lymphoma; 2015 Apr; 56(4):847-57. PubMed ID: 24996442
[TBL] [Abstract][Full Text] [Related]
18. Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC-MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning.
Punt AM; Langenhorst JB; Egas AC; Boelens JJ; van Kesteren C; van Maarseveen EM
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Jun; 1055-1056():81-85. PubMed ID: 28445850
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in the treatment of acute lymphoblastic leukemia: clofarabine.
Jeha S
Hematol Oncol Clin North Am; 2009 Oct; 23(5):1137-44, viii. PubMed ID: 19825457
[TBL] [Abstract][Full Text] [Related]
20. Nonmyeloablative allogeneic hematopoietic stem cell transplant for the treatment of patients with hematologic malignancies using busulfan, fludarabine, and total body irradiation conditioning is effective in an elderly and infirm population.
Brammer JE; Stentz A; Gajewski J; Curtin P; Hayes-Lattin B; Kovacsovics T; Leis JF; Meyers G; Nemecek E; Subbiah N; Frires R; Palmbach G; Avraham GP; Slater S; Maziarz RT
Biol Blood Marrow Transplant; 2015 Jan; 21(1):89-96. PubMed ID: 25445641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
